Onderneming Eli Lilly and Company Berne S.E.

LLY

US5324571083

Farmaceutische producten

Analistenconsensus

Vakgebied

Verkoop per activiteit

Verkoop per regio

Managers

Besturend

Aandelenklasse

Aandeelhouders

Participaties

Bedrijfsgegevens

Bedrijven van de groep

Sector

Verkoop per regio

Ratings voor Eli Lilly and Company

Herzieningen van WPA

Kwartaalwinst - Afwijkingspercentage

Sector Farmaceutische producten - Andere

Vertraagde tijd Berne S.E. Andere beurzen 18:00:02 16-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
684,5 ^CHF	-1,23%		-2,83%	+40,38%

28/06	Atossa Therapeutics verdubbelt de dosis Z-Endoxifen in fase 2-studie naar borstkanker	MT
28/06	EMA zegt dat CHMP positief advies heeft gegeven voor mResvia RSV mRNA-vaccin voor preventie bij volwassenen van 60 jaar en ouder	RE

Eli Lilly and Company is een van de grootste farmaceutische groepen ter wereld. De netto-omzet is als volgt over de therapeutische gebieden verdeeld
- endocrinologie (57,7%): producten voor de behandeling van osteoporose, diabetes en groeiproblemen;
- oncologie (19,5%);
- immunologische ziekten (11,1%);
- neurologie (8,4%): voornamelijk geneesmiddelen voor de behandeling van depressie en schizofrenie;
- overige (3,3%).
De netto-omzet is als volgt geografisch verdeeld: Verenigde Staten (63,9%), Europa (18,1%), Japan (4,9%), China (4,5%) en overige (8,6%).

USD in miljoen	2022	Gewicht	2023	Gewicht	Delta
Human Pharmaceutical Products 100,0 %	28 541	100,0 %	34 124	100,0 %	+19,56%

USD in miljoen	2022	Gewicht	2023	Gewicht	Delta
United States 63,9 %	18 190	63,7 %	21 791	63,9 %	+19,80%
Europe 18,1 %	4 299	15,1 %	6 175	18,1 %	+43,62%
Other Foreign Countries 8,6 %	2 852	10,0 %	2 946	8,6 %	+3,30%
Japan 4,9 %	1 747	6,1 %	1 673	4,9 %	-4,28%
China 4,5 %	1 453	5,1 %	1 540	4,5 %	+5,98%

Managers	Titel	Leeftijd	Van
David Ricks CEO	Chief Executive Officer	56	01-01-96
Ruth Gimeno PSD	President	-	-
David Hyman CTO	Chief Tech/Sci/R&D Officer	-	16-10-23
Alonzo Weems CMP	Compliance Officer	-	01-01-97
Daniel Skovronsky CTO	Chief Tech/Sci/R&D Officer	50	01-01-18
Diogo Rau CTO	Chief Tech/Sci/R&D Officer	-	17-05-21
Johna Norton PRN	Corporate Officer/Principal	57	01-04-17
Edgardo Hernandez PRN	Corporate Officer/Principal	-	01-01-05
Ilya Yuffa PRN	Corporate Officer/Principal	49	-
Ronald DeMattos		-	-

Besturend	Titel	Leeftijd	Van
Gabrielle Greene-Sulzberger BRD	Director/Board Member	63	25-01-21
Ralph Alvarez BRD	Director/Board Member	68	01-04-09
Jon Fyrwald BRD	Director/Board Member	63	01-01-05
Juan Luciano BRD	Director/Board Member	62	01-02-16
William Kaelin BRD	Director/Board Member	66	04-06-12
David Ricks CEO	Chief Executive Officer	56	01-01-96
Jamere Jackson BRD	Director/Board Member	54	01-10-16
Katherine Baicker BRD	Director/Board Member	52	12-12-11
Marschall Runge BRD	Director/Board Member	69	01-09-13
Karen Walker BRD	Director/Board Member	62	01-12-18

	Stemming	Aantal	Vrij verhandelbaar	Bedrijfseigen aandelen	Drijvend Totaal
Aandeel A	1	950 770 386	948 828 662 ( 99,80 %)	365 000 ( 0,0384 %)	99,80 %

Naam	Aandelen	%	Totale waarde
Lilly Endowment, Inc. 10,24 %	97 368 810	10,24 %	79 876 M CHF
Vanguard Fiduciary Trust Co. 7,654 %	72 745 011	7,654 %	59 676 M CHF
PNC Investments LLC 5,412 %	51 438 196	5,412 %	42 197 M CHF
BlackRock Advisors LLC 5,288 %	50 259 761	5,288 %	41 230 M CHF
STATE STREET CORPORATION 3,605 %	34 258 566	3,605 %	28 104 M CHF
Fidelity Management & Research Co. LLC 3,584 %	34 063 734	3,584 %	27 944 M CHF
Capital Research & Management Co. (World Investors) 2,582 %	24 536 055	2,582 %	20 128 M CHF
PRIMECAP Management Co. 2,236 %	21 254 190	2,236 %	17 436 M CHF
T. Rowe Price International Ltd. 2,169 %	20 613 061	2,169 %	16 910 M CHF
JPMorgan Investment Management, Inc. 1,957 %	18 597 930	1,957 %	15 257 M CHF

Naam	Aandelen	%	Totale waarde
Caixa DTVM SA 0,001487 %	424 450	0,001487 %	12 M CHF
Western Asset Management Company DTVM Ltda. 0,000702 %	200 279	0,000702 %	6 M CHF
Safra Asset Management Ltda. 0,000207 %	59 000	0,000207 %	2 M CHF
Bram Bradesco Asset Management S/A DTVM 0,000171 %	48 730	0,000171 %	1 M CHF
Warren Brasil Gestão e Administração e Recursos Ltda. 0,000034 %	9 625	0,000034 %	267 167 CHF
XP Allocation Asset Management Ltda. 0,000014 %	3 884	0,000014 %	107 811 CHF
BTG Pactual WM Gestão de Recursos Ltda. 0,000000 %	137	0,000000 %	3 803 CHF

Naam	Aandelen	%	Totale waarde
IMMUNOCORE HOLDINGS PLC 6.25%	2 548 145	6.25%	124 808 142 $
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. 6.83%	8 084 411	6.83%	44 026 813 $
PROQR THERAPEUTICS N.V. 16.37%	13 371 562	16.37%	26 074 546 $
FOGHORN THERAPEUTICS INC. 7.23%	4 000 000	7.23%	23 320 000 $
AC IMMUNE SA 3.64%	3 615 328	3.64%	16 811 275 $
MICROTECH MEDICAL (HANGZHOU) CO., LTD. 7.60%	21 776 804	7.60%	10 995 108 $
PRECISION BIOSCIENCES, INC. 1.81%	125 405	1.81%	1 617 725 $

Eli Lilly & Co.

Lilly Corporate Center

46285, Indianapolis

+317 276 2000

http://www.lilly.com

Naam	Categorie en sector
Eli Lilly SA Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland.	Pharmaceuticals: Major
Kinsale Financial Services
ELI Lilly & Company (India) Pvt Ltd. ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India.	Pharmaceuticals: Major
Lilly Ventures Fund I LLC Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements.	Investment Managers
Eli Lilly Export SA (Switzerland) Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide.	Medical Distributors
Eli Lilly Group Pension Trustees Ltd. Eli Lilly Group Pension Trustees Ltd. Financial ConglomeratesFinance Part of Eli Lilly & Co., Eli Lilly Group Pension Trustees Ltd. operates as a British dormant company. The company is based in Basingstroke, UK.	Financial Conglomerates
Eli Lilly (Suisse) SA
Eli Lilly Vostok SA
Eli Lilly Services India Pvt Ltd. Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015.	Pharmaceuticals: Major
Lilly Global Nederland Holdings BV Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The company is based in Utrecht, Netherlands.	Financial Conglomerates
Lilly Nederland Finance BV Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The company is based in Utrecht, Netherlands.	Miscellaneous Commercial Services
Eli Lilly Kinsale Ltd. Eli Lilly Kinsale Ltd. Pharmaceuticals: OtherHealth Technology Eli Lilly Kinsale Ltd., part of Eli Lilly & Co., is a company headquartered in Kinsale, Ireland, that manufactures medicines.	Pharmaceuticals: Other

Trading rating

Beleggingsrating

ESG Refinitiv

Meer adviezen

Verkoop

Koop

Gemiddeld advies

Kopen

Aantal analisten

Laatste slotkoers

905,4 USD

Gemiddelde koersdoel

868,9 USD

Spread / Gemiddelde doel

-4,03%

Consensus

Bedrijfscijfers

De agenda van het bedrijf

Gezondheidszorg

Farmaceutisch en medisch onderzoek

Farmaceutische producten

Farmaceutische producten

Farmaceutische producten - Andere

	Vaira. 1 jan.	Kapi.
NOVO NORDISK A/S	+44,05%	641 mld.
JOHNSON & JOHNSON	-6,75%	352 mld.
MERCK & CO., INC.	+13,56%	314 mld.
ABBVIE INC.	+10,68%	303 mld.
ASTRAZENECA PLC	+16,57%	242 mld.
ROCHE HOLDING AG	+2,04%	224 mld.
NOVARTIS AG	+13,31%	218 mld.
AMGEN INC.	+8,48%	168 mld.
PFIZER, INC.	-2,81%	159 mld.

Farmaceutische producten - Andere